2022 Fiscal Year Final Research Report
Development of Hydrophilic Boron Cluster Containing Molecular-Targeted Drugs
| Project/Area Number |
20K05753
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 37030:Chemical biology-related
|
|---|
| Research Institution | Osaka Metropolitan University (2022)
Osaka Prefecture University (2020-2021) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | BNCT / ホウ素クラスター / セラノスティック |
|---|
| Outline of Final Research Achievements |
Recently, research on the development of so-called "theranostic" agents applicable to both diagnosis and treatment has been progressing, especially with the aim of applying them to novel cancer therapies.
In this study, to develop multifunctional agents applicable not only to cancer diagnosis but also to boron neutron capture therapy (BNCT), which is attracting attention as a minimally invasive cancer therapy. For this purpose, we selected BSH, an icosahedral boron cluster molecule, as the core molecule, and designed and synthesized boron drugs by introducing "tumor targetting molecules" and "labeling molecules" such as fluorescent molecules for imaging into sulfur atoms, and evaluated their usefulness as theranostic BNCT drugs. The evaluation of the boron drug as a theranostic BNCT agent was elucidated.
|
| Free Research Field |
ケミカルバイオロジー
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、がんの診断だけではなく、低侵襲ながん治療として注目されているホウ素中性子捕捉療法（BNCT）に適用可能な薬剤の開発を目指すものである。このためにホウ素１２原子から構成されホウ素含有率の非常に高いスルホニオドデカボレートを用い、様々な腫瘍集積性分子へ多量のホウ素原子と蛍光分子を同時に導入する手法を確立した。さらに、本手法を用いて調製したホウ素化抗体は赤外蛍光を用いて薬剤分布を解析可能なセラノスティック型BNCT用薬剤として有望な化合物であるを明らかとした。
今後、本研究で開発された化合物群を活用することにより、有用なセラノスティック型BNCT用薬剤の開発につながると期待できる。
|
